- Research article
- Open Access
- Open Peer Review
Histone methylation levels correlate with TGFBIp and extracellular matrix gene expression in normal and granular corneal dystrophy type 2 corneal fibroblasts
© Maeng et al. 2015
- Received: 21 April 2015
- Accepted: 4 November 2015
- Published: 9 November 2015
TGFβ1-induced expression of transforming growth factor β-induced protein (TGFBIp) and extracellular matrix (ECM) genes plays a major role in the development of granular corneal dystrophy type 2 (GCD2: also called Avellino corneal dystrophy). Although some key transcription factors are known, the epigenetic mechanisms modulating TGFBIp and ECM expression remain unclear. We examined the role of chromatin markers such as histone H3 lysine methylation (H3Kme) in TGFβ1-induced TGFBIp and ECM gene expression in normal and GCD2-derived human corneal fibroblasts.
Wild-type (n = 3), GCD2-heterozygous (n = 1), and GCD2-homozygous (n = 3) primary human corneal fibroblasts were harvested from human donors and patients prepared. Microarray and gene-expression profiling, Chromatin immunoprecipitation microarray analysis, and Methylated DNA isolation assay-assisted CpG microarrays was performed in Wild-type and GCD2-homozygous human cells.
Transcription and extracellular-secretion levels of TGFBIp were high in normal cells compared with those in GCD2-derived cells and were related to H3K4me3 levels but not to DNA methylation over the TGFBI locus. TGFβ1 increased the expression of TGFBIp and the ECM-associated genes connective tissue growth factor, collagen-α2[Ι], and plasminogen activator inhibitor-1 in normal corneal fibroblasts. Increased levels of gene-activating markers (H3K4me1/3) and decreased levels of repressive markers (H3K27me3) at the promoters of those gene accompanied the changes in expression. TGFβ1 also increased recruitment of the H3K4 methyltransferase MLL1 and of SET7/9 and also the binding of Smad3 to the promoters. Knockdown of both MLL1 and SET7/9 significantly blocked the TGFβ1-induced gene expression and inhibited TGFβ1-induced changes in promoter H3K4me1/3 levels. Those effects were very weak, however, in GCD2-derived corneal fibroblasts.
Taken together, the results show the functional role of H3K4me in TGFβ1-mediated TGFBIp and ECM gene expression in corneal fibroblasts. Pharmacologic and other therapies that regulate these modifications could have potential cornea-protective effects for granular corneal dystrophy.
- Extracellular matrix
- Histone methylation
Granular corneal dystrophy type 2 (GCD2, also called Avellino corneal dystrophy) is an autosomal dominant disorder caused by an arginine-to-histidine substitution at codon 124 (R124H) of the transforming growth factor β-induced gene (TGFBI) on chromosome 5q31.8. TGFBI encodes a protein of 683 amino acids (TGFBIp) [1, 2]. TGFBIp is an extracellular matrix (ECM) protein that is structurally homologous to the axon-guidance protein fasciclin I [3–5]. TGFBIp contains four tandem repeats of fasciclin I domains and an EMI protein-protein interaction domain and plays a key role in a variety of cellular responses including adhesion, migration, proliferation, angiogenesis, and wound healing [6–8]. The age-dependent, progressive accumulation of hyaline and amyloid-containing TGFBIp in the corneal stroma is a hallmark of GCD2, which is characterized by the production of TGFBIp in the corneal epithelia and stroma, interfering with corneal transparency . Moreover, homozygous R124H mutations in TGFBI cause the severe phenotype of GCD2 characterized by early onset and confluent superficial opacity [10, 11]. The molecular mechanisms and cellular role of TGFBIp in corneal dystrophy pathogenesis are poorly understood.
TGFβ1 induces the progressive accumulation of TGFBIp and ECM proteins such as collagens, fibronectin, and keratin in the corneal epithelia and stroma [12–14]. TGFβ1 increases ECM accumulation through the induction of its downstream effector, connective tissue growth factor (CTGF) [15, 16], and by decreasing matrix degradation through the inhibition of proteases or the activation of protease inhibitors such as plasminogen activator inhibitor-1 (PAI-1) in glomerular mesangial cells . TGFβ1 can regulate TGFBIp expression through Smad transcription factors and E-box-dependent mechanisms [18–22]. However, the subtle nuclear-chromatin mechanisms involved in the TGF-β1-induced expression of key ECM genes in corneal fibroblasts are not clear.
Gene regulation by extracellular stimuli involves not only transcription factors binding to their cognate DNA binding sites but also epigenetic changes in chromatin without alterations in DNA sequence. Post-translational modifications, including acetylation, methylation, and ubiquitination at key lysines, on the amino-terminal tails of nucleosomal histones such as H3 and H4 play a key role in modulating chromatin structure and gene transcription [23, 24]. They form a “histone code” that can dictate the transcriptional outcomes of gene activation or repression . In general, the acetylation of H3 lysines (H3KAc) is associated with active gene transcription, whereas the methylation of H3 lysines (H3Kme) can be associated with either active or inactive gene promoters, depending on the position of the modified lysine. H3KAc is mediated by histone acetyl transferases, whereas H3Kme is mediated by histone methyltransferases (HMTs). HMTs can mono-methylate, di-methylate, or tri-methylate (H3Kme1, H3Kme2, or H3Kme3, respectively) specific lysine residues, thereby adding another epigenetic regulatory layer .
The methylation of the fourth lysine in H3 (H3K4me) is usually associated with gene activation and transcriptional elongation and is mediated by HMTs such as SET1, MLL1-4, and SET7/9 [24, 26–28]. H3K9me, on the other hand, is generally associated with gene repression and is mediated by HMTs such as SUV39H1, G9a, and SETDB1/ESET . Other H3 lysines, including H3K27, H3K36, and H3K79, can also be methylated to various degrees . In addition, the discovery of histone lysine demethylases has added another dimension to gene regulation . Together, these factors create a fine balance of gene regulation, a disruption of which could result in abnormal gene expression and disease phenotypes.
It is not known whether lysine methylation in the H3 promoter plays a role in the TGFβ1-induced transcription of TGFBIp and ECM-associated genes in corneal fibroblasts. Here, we show that the transcription and ECM secretion levels of TGFBIp are high in normal cells compared with those in GCD2 cells and are related to H3K4me3 levels. We also show that TGFβ1 leads to the enrichment of H3K4me1/3 and the depletion of H3K27me3 markers on the promoters of TGFBIp and ECM-associated genes in corneal fibroblasts. Furthermore, H3K4, HMT, MLL1, and SET7/9 all seemed to play a role in the TGFβ1-induced expression of TGFBIp and ECM genes. These data show novel epigenetic mechanisms of TGFβ1 actions in corneal fibroblasts related to TGFBIp and ECM deposition and GCD2 pathogenesis.
Recombinant TGFβ1 was obtained from R&D Systems (Minneapolis, MN); normal rabbit IgG, normal mouse IgG, and ChIP-Grade Protein A/G Magnetic Beads were obtained from Thermo Scientific, (Rockford, IL, USA). The following antibodies were used in western-blot analyses and ChIP assays: anti-smad3 (ab28379), anti-SET7/9 (ab13731), anti-histone H3 (ab100938), anti-histone H3 trimethyl K9 (ab8898), and anti-H3 trimethyl K27 (ab1782) from Abcam (Cambridge, MA); anti-MLL1 (05–765), anti-H3 monomethyl K4 (07–436), and anti-H3 trimethyl K4 (07–473) from Millipore (Millipore Corp., Bedford, MA); anti-TGFBIp (AF2935) from R&D Systems; and anti-β-actin (A-5441) from Sigma-Aldrich (St. Louis, MO). MLL1 shRNA lentivirus (sc-38039-v), SET7/9 shRNA lentivirus (sc-44094-v), and control shRNA lentivirus (sc-108080) was purchased from Santa Cruz Biotechnology Inc. (Heidelberg, Germany).
Isolation and culture of primary corneal fibroblasts
Wild-type (n = 2) and GCD2-homozygous (n = 2) (Arg124His mutation) primary human corneal fibroblasts were harvested from human donors (age matched) and patients prepared using a previously published method . Donor confidentiality was maintained according to the Declaration of Helsinki, and the Severance Hospital IRB Committee (CR04124), Yonsei University approved the protocol. The wild-type and GCD2 cells were diagnosed by DNA sequencing of TGFBI mutations. After the removal of the corneal buttons from the donors for penetrating keratoplasty, the remaining corneal rims were harvested for culture of the corneal fibroblasts. The medical records of the donors from the eye bank of Yonsei University Severance Hospital did not show any genetic or systemic metabolic disease. The fibroblasts grown from the pieces of corneal rims were treated as healthy controls. The corneal fibroblast cells were cultured in DMEM supplemented with 10 % fetal bovine serum at 37 °C in a humidified incubator with 95 % air and 5 % CO2.
Microarray and gene-expression profiling
Transcriptional profiles were evaluated in two independent cell preparations using a cDNA microarray (GeneChip Human Gene 1.0 ST Array, GeneChip; Affymetrix, Santa Clara, CA) containing approximately 29,000 genes. To determine the variation and average changes (x-fold) in the expression of different genes in each sample and to compare the samples, we analyzed four samples (normal sample pairs 1 and 2 (age matched) and GCD2-homozygous (Arg124His mutation) sample pairs 1 and 2) in an additional microarray analysis without total RNA pooling. Total RNA was extracted from the cells (TRIzol; Invitrogen, Carlsbad, CA), followed by purification (RNeasy kit; Qiagen, Valencia, CA) to remove residual DNA. The concentration of total RNA was determined by UV spectrophotometry (ND-1000 UV–vis Spectrophotometer; Nanodrop Technologies, Wilmington, DE). Two quality controls were used for each RNA sample: (1) an A260/A280 ratio between 1.7 and 2.3 and (2) an electropherogram showing two distinct ribosomal peaks corresponding to 18S and 28S RNAs, respectively, at a ratio of 28S/18S > 0.5 with minimal or no degradation.
100 ng of total RNA was used for the microarray experiment. GeneChip Human Gene 1.0 ST Arrays (Affymetrix, Santa Clara, USA) were used. Whole microarray experiment was performed according to the manufacturers protocol. The Affymetrix GeneChip Whole Transcript (WT) sense Target Labeling Assay is designed to generate amplified and biotynylated sense-strand DNA targets from the entire expressed genome. Protocol is optimized for the use with the GeneChip Sense Target (ST) Arrays, where the probes are distributed throughout the entire lenght of each transcript. At first 100 ng of total RNA was mixed with Poly-A RNA controls (GeneChip Eukaryotic Poly-A Control Kit, Affymetrix, Santa Clara, USA). Subsequently cDNA sysnthesis was performed with random hexamers tagged with a T7 promoter sequence (GeneChip WT cDNA Synthesis and Amplification Kit, Sub-kit 1: GeneChip WT cDNA Synthesis Kit; Affymetrix, Santa Clara, USA). The double-stranded cDNA was then used as a template to produce many copies of antisense cRNA (GeneChip WT cDNA Synthesis and Amplification Kit, Sub-kit 2: GeneChip WT cDNA Amplification Kit; Affymetrix, Santa Clara, USA). cRNA was treated with the cleanup procedure (GeneChip IVT cRNA, cDNA Cleanup Kit; Affymetrix, Santa Clara, USA). Subsequently cRNA yield was determined by spectrophotometric measurement (NanoDrop ND-1000; Thermoscientific). 10 μg of cRNA was then used in the second cycle of cDNA synthesis. The random hexamers were used to prime riverse transcription of the cRNA to produce single-stranded DNA in the sense orientation (GeneChip WT cDNA Synthesis and Amplification Kit, Sub-kit 1: GeneChip WT cDNA Synthesis Kit; Affymetrix, Santa Clara, USA). During this step of the procedure, in order to reproducibly fragment ssDNA, dUTP was incorporated. Subsequently, ssDNA was then proceed with the cleanup procedure (GeneChip IVT cRNA, cDNA Cleanup Kit; Affymetrix, Santa Clara, USA). DNA yield was determined by spectrophotometric measurement (NanoDrop ND-1000; Thermoscientific).
5 μg of single-stranded DNA was treated with a combination of two enzymes: uracil DNA glycosidase (UDG) and apurinic/apyrimidinic endonuclease 1 (APE 1), specifically recognizing the dUTP nucleotides and breaking the DNA strand (GeneChip WT Terminal Labeling Kit; Affymetrix, Santa Clara, USA). Subsequently, fragmented DNA was labeled by terminal deoxynucleotidyl transferase (TdT) with the DNA Labeling Reagent, that was covalently linked to biotin (GeneChip WT Terminal Labeling Kit; Affymetrix, Santa Clara, USA). Then fragmented and labeled DNA was hybridized with the GeneChip Human Gene 1.0 ST Array (Affymetrix, Santa Clara, USA). Apart from DNA, hybridization cocktail included: Eukaryotic Hybridization Controls (bioB, bioC, bioD, cre), Control Oligonucleotide B2 (GeneChip Hybridization Control Kit; Affymetrix, Santa Clara, USA), 2x Hybridization Mix, DMSO, water (GeneChip Hybridization, Wash and Stain Kit- Hybridization Module; Affymetrix, Santa Clara, USA). Hybridization was performed in 450C/ 60 rpm/ 17 h ±1 h at hybridization oven (GeneChip Hybridization Oven 640; Affymetrix, Santa Clara, USA).
After the hybridization, arrays were registered in GeneChip Operating Software (GCOS), and subsequently washed and stained with the use of GeneChip Fluidics Station 450 (Affymetrix, Santa Clara, USA) and FS450_0007 protocol (GeneChip Hybridization, Wash and Stain Kit-Stain Module; Wash Buffer A; Wash Buffer B; Affymetrix, Santa Clara, USA). After the wash protocol was finished arrays were scanned with the GeneChip Scanner 3000 7G (Affymetrix, Santa Clara, USA) controlled by GeneChip Operating Software. The raw signal intensities were normalized (GeneChip Operating Software [GCOS] algorithm; Affymetrix); and the data were analyzed (Gene Chip DNA Analysis Software [GDAS], ver. 2.0) according to the Affymetrix GeneChip Expression Analysis Technical Manual (http://www.affymetrix.com). We detected a twofold change in differential gene expression between the normal and GCD2-homozygous (Arg124His mutation) samples. Expression of ECM-associated genes (TGFBIp, COL1A2, CTGF, and PAI-1) and H3K4 methyltransferase genes (MLL1, MLL2, ASH1L, SMYD3, SET7/9 and SETMAR) is presented as the log2 ratio. For statistical analysis, we used a two-tailed, unpaired Student’s t-test (significance threshold P < 0.05) to assess differences between the two cell types.
Lentiviruses containing human SET7/9, MLL1, and control shRNA, respectively, were purchased from Santa Cruz Biotechnology Inc. and used to infect corneal fibroblasts according to the manufacturer’s instructions. Infected cells were selected using puromycin.
Real-time quantitative reverse transcription PCR
Total RNA was isolated from corneal fibroblasts by extraction in TRIZOL reagent (Invitrogen, Carlsbad, CA). Using the Power SYBR Green RNA-to-CT™ 1-Step kit (Applied Biosystems, Foster City, CA, USA) and StepOnePlus™ (Applied Biosystems, Foster City, CA, USA), mRNA expression of GAPDH, TGFBIp, collagen type I alpha 2 (COL1A2), plasminogen activator inhibitor-1 (PAI-1), and CTGF was measured according to the manufacturer’s instructions. The PCR conditions for all the genes were as follows: 48 °C for 30 min, 95 °C for 10 min, then 40 cycles of 95 °C for 15 s and 60 °C for 1 min. The results were based on cycle threshold (Ct) values. We calculated the differences between the Ct values for the experimental genes and GAPDH (a reference gene) and graphed the results as the ratio of each RNA level to the calibrator sample level. The primers used for gene amplification were the following: TGFBI, 5′-CACAGTCTTTGCTCCCACAA-3′ (sense) and 5′-CTCCGCTAACCAGGATTTCA-3′ (antisense); GAPDH, 5′-ATGGGGAAGGTGAAGGTCG-3′ (sense) and 5′-GGGGTCATTGATGGCAACAATA-3′ (antisense); COL1A2, 5′- ATGGCTACCCAACTTGCCTT-3′(sense) and 5′-ACAGCCTTTTTCAGGTTGCC-3′ (antisense); PAI-1, 5′-CTGTCATAGTCTCAGCCCGC-3′ (sense) and 5′-AAAGGACTGTTCCTGTGGGG-3′ (antisense); and CTGF, 5′-GTGCATCCGTACTCCCAAAA-3′ (sense) and 5′-ATCGGCCGTCGGTACATACT-3′(antisense). Three independent experiments were performed, and statistical analysis was carried out using Newman-Keuls multiple comparison tests.
Chromatin immunoprecipitation for microarray analysis
Chromatin immunoprecipitation (ChIP) assays were performed using the EpiQuik TM Chromatin Immunoprecipitation Kit (Epigentek) based on the protocol provided by the supplier (Epigentek Group Inc., Brooklyn, NY). Briefly, samples containing 4 × 106 human corneal fibroblasts were chemically cross-linked by the addition of fresh 11 % formaldehyde solution (1:10 volumetric ratio of solution to sample) for 15 min at room temperature. The cells were then rinsed twice with 1× PBS, resuspended in CP3 lysis buffer containing a protease-inhibitor cocktail, and sonicated until the cross-linked chromatin was sheared to an average DNA fragment length of 200–1000 bp. One per cent of the sonicated lysate was used to quantify the total amount of DNA present in the different samples before immunoprecipitation (input). The sonicated samples were immunoprecipitated with H3K4me3 (Millipore, Millipore Corp., Bedford, MA) and H3K27me3 (Abcam, Cambridge, MA) antibodies using the EpiQuik TM Chromatin Immunoprecipitation Kit (Epigentek). Cross-linking between DNA and proteins was reversed by heating the samples at 65 °C for 15 min followed by Proteinase K digestion at 65 °C for 1.5 h. After cleaning on spin columns, the DNA was eluted in 10 mM Tris–EDTA buffer.
Chromatin immunoprecipitation microarray analysis
The immunoprecipitated and input DNA was amplified using a whole-genome amplification kit (GenomePlex® Complete Whole Genome Amplification Kit, Sigma, USA) according to the manufacturer’s instructions. The amplified samples were purified using the QIAQuick PCR clean-up kit (Qiagen). Labeling reactions were performed with 4 μg purified amplified DNA and a Bioprime labeling kit (Invitrogen) according to the manufacturer’s instructions in a volume of 50 μl with a modified dNTP pool containing 120 μM each of dATP, dGTP, and dCTP; 60 μM dTTP; and 60 μM Cy5-dUTP (for the immunoprecipitated sample) or Cy3-dUTP (for the input sample). Labeled targets were subsequently purified using the QIAQuick PCR clean-up kit (Qiagen). Then, the dye-labeled DNA samples were purified and quantified using an ND-1000 spectrophotometer (NanoDrop Technologies, Inc., Wilmington, DE). After checking the labeling efficiency, each sample containing 2.5–5.0 μg cyanine 3-labeled and cyanine 5-labeled DNA target was mixed and then resuspended with 2X hybridization buffer, Cot-1 DNA, Agilent 10X blocking agent, and de-ionized formamide. Before hybridization to the array, the 260-μl hybridization mixtures were denatured at 95 °C for 3 min and incubated at 37 °C for 30 min. The hybridization mixtures were centrifuged at 17,900 g for 1 min and directly pipetted onto the Human Promoter 1 M microarray (Agilent Technology, USA). The arrays were hybridized at 65 °C for 40 h using an Agilent Hybridization oven (Agilent Technology, USA). The hybridized microarrays were washed according to the manufacturer’s protocol (Agilent Technology, USA).
Data acquisition and analysis
The hybridization images were analyzed using an Agilent DNA Microarray Scanner (Agilent Technology, USA), and the data were quantified using the Agilent Feature Extraction software (Agilent Technology, USA). The preprocessing of the raw data and the normalization steps were performed using the Agilent Genomic Workbench software according to the manufacturer’s instructions (Agilent, USA). The background-corrected intensity data were normalized by blank subtraction followed by intra-array LOWESS normalization. The peak detection was performed with Pre-defined Peak Shape detection v2.0 with P-value < 0.01 as the threshold of significance for a non-parametric test and a peak-score > 5 for an EVD-based score (based on T. Kaplan & N. Friedman “Model-Based Analysis of High resolution Chromatin Immunoprecipitation” Technical Report 2006–11, School of Computer Science & Engineering, Hebrew University 2006).
Methylated DNA isolation assay-assisted CpG microarrays
Methylated DNA isolation assay (MeDIA)-assisted CpG microarray analysis was performed as described previously with slight modification . Briefly, 1.0 μg sonic-fragmented genomic DNA from the test and control tissues, respectively, was incubated with 2 μg recombinant MBD2bt protein for 4 h at 4 °C on a rocking platform. The enriched, methylated DNA was amplified using a whole-genome amplification kit (GenomePlex®, Sigma, USA) according to the manufacturer’s protocol. The amplified DNA in the control and test samples was labeled with Cy5 and Cy3, respectively. The labeled samples were purified using a PCR purification kit (Qiagen, USA) and then co-hybridized to human promoter 1 M microarrays (Agilent, Santa Clara, CA, USA) according to manufacturer’s instructions.
Microarray data analysis
The hybridized images were analyzed using an Agilent DNA Microarray Scanner (Agilent Technology, USA), and the data were quantified using the Agilent Feature Extraction software (Agilent Technology, USA). The preprocessing of raw data and the normalization steps were performed using GeneSpring 7.3.1 (Agilent, USA). The background-corrected intensity data were normalized using the intensity-dependent LOWESS method to remove the dye bias within each array as recommended by the manufacturer (Agilent, USA). To select the multiple-probes-enriched target genes, the first level of data filtering involved the removal of all probes that showed only methylation (≥ twofold enrichment of the methylated fraction in test samples versus control samples) or non-methylation (≤ twofold enrichment of the non-methylated fraction in test samples versus control samples). To increase the reliability of the results, we selected genes with probes in at least two adjacent probes.
Chromatin immunoprecipitation assays
ChIP assays were performed, and ChIP-enriched DNA was analyzed by qPCR as described previously . Briefly, cells were fixed with 1 % formaldehyde at 37 °C for 10 min, washed with cold PBS containing protease inhibitors, and lysed in Tris (pH 8.1) containing 1 % SDS, 1 mM PMSF, and complete protease-inhibitor cocktail. The cell lysates were sonicated into 500-bp chromatin fragments, diluted in ChIP dilution buffer, and immunoprecipitated overnight at 4 °C with the appropriate antibodies, with IgG control, or without antibody (no-antibody control). The next day, immune complexes were collected on ChIP-Grade Protein A/G Magnetic Beads (Thermo Fisher Scientific Inc., Rockford, IL USA), and the beads were washed to remove nonspecific binding. The DNA was eluted from the beads, the crosslinks were reversed, and the DNA was extracted. The ChIP-enriched DNA samples and the input DNA samples were analyzed by qPCR with SYBR reagent in a real-time PCR machine (ABI 7300; Applied Biosystems) using primers specific for the TGFBI, Col1a1, CTGF, or PAI-1 promoters spanning Smad binding elements (SBEs). All reactions were performed in triplicate in a final volume of 20 μl. Dissociation curves were run to detect nonspecific amplification, and we confirmed that single products were amplified in each reaction. The qPCR data were analyzed using the 2-ΔΔCt method, as described previously , and normalized with the input samples. The results were expressed as the fold change relative to the control. In all of the experiments, we verified that the ChIP samples obtained with specific antibodies exhibited significant enrichment relative to the IgG or no-antibody controls. The primers used for the ChIP-enriched DNA were: TGFBIp, 5′-TACCTGCCTTGAGCTCCTCC-3′ (sense) and 5′-GTGGGGTCCTCACCTTGGTA-3′ (antisense); COL1A2, 5′-CTCCGACGTGTCCCATAGTG-3′ (sense) and 5′-CTTTTGAGGCTTTCAAGGGG-3′ (antisense); PAI-1, 5′-AGTCTGGACACGTGGGGAGT-3′ (sense) and 5′-GCCAGCCACGTGATTGTCTA-3′ (antisense); and CTGF, 5′-TCTGTGAGCTGGAGTGTGCC-3′ (sense) and 5′-ACAGGGACATTCCTCGCATT-3′ (antisense).
Cell lysates were fractionated by SDS-PAGE and transferred to PVDF membranes. The blocked membranes were incubated with the appropriate antibody, and the immunoreactive bands were visualized with a chemiluminescent reagent as recommended by Amersham Biosciences, Inc.
All experiments were repeated at least three times. Data are presented as the mean ± standard error (SE), and statistical comparisons between groups were performed by one-way ANOVA followed by Tukey’s test.
Transcription and extracellular-secretion levels of TGFBIp were high in wild-type cells compared with those in GCD2 homozygous cells and were related to H3K4me3 levels but not to DNA methylation
Not only mutation of TGFBIp gene, but also regulation of TGFBIp expression is very important cause of in GCD2.
We next examined whether the difference in TGFBIp gene expression was associated with changes in either the active epigenetic marker H3K4me3 or the repressive epigenetic marker H3K27me3 in the H3 promoter. As shown in Fig. 1e, f, the H3K4me3 levels in the Smad Binding Element (SBE) of the TGFBIp promoter and in the TSS of the TGFBIp gene were much higher in the wild-type cells compared with those in the GCD2-homozygous cells, similar to the TGFBIp mRNA transcription levels. The H3K27me3 levels were very low in both the wild-type and the GCD2-homozygous cells, however, and were not different between the two cell types. To further confirm the association between H3K4me3 levels and TGFBIp mRNA transcription levels, we analyzed wild-type (n = 3), GCD2-heterozygous (n = 1), and GCD2-homozygous (n = 3) corneal fibroblasts. As shown in Additional file 1: Figure S1A–C, the TGFBIp mRNA transcription levels and extracellular secreted-protein levels were much higher in the wild-type cells compared with those in the GCD2 cells and were strongly related to the H3K4me3 levels. The intracellular TGFBIp protein levels were not related to the mRNA or H3K4me3 levels in the GCD2 cells, however (Additional file 1: Figure S1D).
TGFβ1 increased the expression of TGFBIp and ECM-associated genes and Smad3 recruitment to the TGFBIp and ECM-associated gene promoters
TGFβ1 enhanced H3K4me1/3 levels on the promoters of TGFBIp and ECM-associated genes
TGFβ1 increased MLL1 recruitment to the TGFBIp and ECM-associated gene promoters
MLL1 and SET7/9 knockdown attenuated the TGFβ1-induced expression of the TGFBIp and ECM-associated genes
To investigate the role of SET7/9 in the expression of the TGFBIp and ECM genes, cells were infected with shSET7/9 or shCont lentivirus, and protein levels were analyzed by western blot. As shown in Additional file 1: Figure S3A, total H3K4me1 levels were clearly decreased in the SET7/9 knockdown cells compared with the shCont cells. In addition, the TGFBIp protein levels were inhibited in the cells infected with shSET7/9 (Additional file 1: Figure S3A). Furthermore, TGFβ1-induced TGFBIp protein and mRNA levels were inhibited by shSET7/9 (Additional file 1: Figure S3B, C) in wild-type corneal fibroblasts. The GCD2-homozygote cells showed very weak TGFBIp expression and inhibition induced by TGFβ1 and shSET7/9, respectively (Additional file 1: Figure S3B, C). TGFβ1-induced COL1A2, PAI-1, and CTGF mRNA levels were also partially inhibited by shSET7/9 lentivirus infection (Additional file 1: Figure S3D), whereas no significant increase and decrease induced by TGFβ1 and shSET7/9, respectively, was observed in the GCD2-homozygous cells (Additional file 1: Figure S3D). Thus, SET7/9 likely partially mediates the induction of H3K4me1 by TGFβ1 in corneal fibroblasts. Collectively, these results suggest that MLL1 and SET7/9 are involved in basal TGFBIp expression and TGFβ1-induced TGFBIp and ECM-associated gene expression.
MLL1 and SET7/9 knockdown attenuated the TGFβ1-induced increase in H3K4me1/3 levels on the promoters of the TGFBIp and ECM-associated genes
To better understand the roles of MLL1 and SET7/9 in TGFBIp expression, cells were co-infected with shMLL1 and shSET7/9, and TGFBIp mRNA levels were analyzed by RT-qPCR. As shown in Fig. 8b, shMLL1 and shSET7/9 co-infection completely inhibited TGFβ1-induced TGFBIp mRNA levels compared with shMLL1 or shSET7/9 single infection, providing evidence that both MLL1 and SET7/9 mediate TGFβ1-induced TGFBIp expression by regulating H3K4me1/3.
In GCD2 pathogenesis, mutations in the TGFBI gene important, but the regulation of TGFBIp expression is also very important. We confirmed that mRNA transcription and extracellular-secretion levels of TGFBIp were high in wild-type corneal fibroblasts compared with those in GCD2-homozygous cells. The expression pattern was strongly related to H3K4me3 levels but not to DNA methylation over the TGFBI locus. Intracellular TGFBIp levels were similar in wild-type and GCD2-homozygous cells, although TGFBIp mRNA transcription and extracellular secreted-protein levels were much lower in GCD2-homozygous cells compared with wild-type cells, because mutant TGFBIp can accumulate in GCD2 corneal fibroblasts as a result of either impaired degradation or delayed extracellular secretion . The abnormal conditions within GCD2 cells caused by mutant-TGFBIp accumulation may weaken responses to exogenous stimuli such as TGFβ1 compared with those in wild-type cells.
Alternately, the observed differences in histone modification in GCD2 fibroblasts compared to normal cells may be due to the reduced expression of TGFBI in the mutant cells. Much less TGFBIp is secreted from mutant than from wild type cells. However, intracellular TGFBIp is at similar levels in both cell types. Given the reduced secretion of the protein in mutant cells, less transcription is required to maintain intracellular protein levels and negative feedback would suppress transcription in mutant relative to wild type cells. Thus, it is expected that levels of H3K4me3, a well-known marker of active transcription, would be reduced at the promoter of the TGFBI gene. Our data show that the transcription of TGFBI and associated ECM genes is increased upon treatment with TGFβ1 and that H3K4me3 levels again correlate with expression. These effects are reduced, but not eliminated, in mutant cells. The association of active histone modifications with levels of transcription may not represent proof of a causative link. Rather, it is more likely that the accumulation of TGFBIp is driving the altered transcription pattern in mutant cells.
In our study, we found that TGFβ1 can up-regulate TGFBIp and ECM-associated genes such as COL1A2, PAI-1, and CTGF in corneal fibroblasts. TGFBIp expression induced by TGFβ1 was seen previously in corneal fibroblasts, but our study is the first to demonstrate increases in the expression of other ECM genes that may coagulate with TGFBIp in the corneas of patients with GCD2. We observed that TGFβ1 increased Smad3 recruitment to the TGFBIp and ECM-associated gene promoters in corneal fibroblasts. TGFBIp and ECM-associated genes have conserved SBEs in their promoters, suggesting that gene expression could be similarly regulated under conditions such as TGFβ1 stimulation.
We examined changes in key epigenetic chromatin markers, including H3K27me3 and H3K4me1/3 levels, on the TGFBIp and ECM-associated gene promoters. Our results showed that those markers, along with H3K27 histone de-methylases (HDMs) and the MLL1 and SET7/9 HMTs, are involved in the TGFβ1-induced up-regulation of TGFBIp and ECM-associated genes in corneal fibroblasts. We showed that the up-regulation of H3K4me1/3 markers usually associated with active chromatin occurs in parallel with the down-regulation of H3K27me3 by TGFβ1, suggesting that those regulatory mechanisms can further contribute to the increased gene expression. Recent studies showed that methylated H3K4 correlates with transcriptionally competent chromatin and is associated with active genes [25–27], supporting our observation that TGFβ1 increased the expression of the TGFBIp and ECM genes in corneal fibroblasts and that such expression was positively correlated with increased H3K4me1and H3K4me3 levels on the associated promoters.
Increasing evidence shows that H3K27me3 markers are recognized by polycomb protein and generally correlate with gene silencing and transcriptional repression [26, 37, 38]. Our results showed for the first time that TGFβ1 decreased H3K27me3 levels on the TGFBIp and ECM gene promoters and that those levels were inversely correlated with the increased expression of the genes, further supporting the notion that a relief of transcriptional repression caused by decreases in repressive chromatin histone modifications may contribute to the increased expression of TGFBIp and ECM genes induced by TGFβ1. Collectively, our observations show that increases in H3K4me1/3 and decreases in H3K27me3 at the TGFBIp and ECM gene promoters in the presence of TGFβ1 in corneal fibroblasts are correlated with the TGFβ1-induced up-regulation of those genes.
Furthermore, we showed not only an increase in the recruitment of the H4K4 HMTs MLL1 and SET7/9 at the TGFBIp and ECM gene promoters but also a decrease in the recruitment of H4K27 HMT in corneal fibroblasts stimulated by TGFβ1, suggesting that the H4K4 HMT MLL1 is involved in the TGFβ1-induced up-regulation of the TGFBIp and ECM genes in corneal fibroblasts. This was supported by our observations that MLL1 and SET7/9 gene silencing partially, but significantly, blocked the expression of the TGFβ1-induced TGFBIp and ECM genes. The knockdown of MLL1 and SET7/9 with shRNAs could decrease global H3K4me1 and H3K4me3 levels, suggesting that H3K4me1/3 mediated by MLL1 and SET7/9 plays a key role in TGFBIp and ECM-associated gene expression and that MLL1 and SET7/9 are potential therapeutic targets for the treatment of ECM-accumulation disorders such as GCD2. The observed increases in H3K4me3 might synergize with other complementary events occurring on the TGFBIp and ECM-associated gene promoters, such as increases in H3K4me1 and decreases in H3K27me3, to enhance TGFBIp and ECM gene expression in response to TGFβ1. In addition, the HMTs and HDMs, as well as the HATs and histone deacetylases, regulating the complementary chromatin markers may also play cooperative roles. Additional studies are needed to assess those factors, including the role of the HMTs that mediate H3K4me1/3 and H3K27me3. It was suggested that the H3K4me1/3 mediated by MLL1 and SET7/9 functions in transcriptional activation by competing with histone deacetylases to enhance H3-K9 acetylation and prevent H3-K9 methylation [39, 40]. MLL1 and SET7/9 can methylate non-histone proteins including p53 [41, 42], DNMT1 , TAF10 , and p65 [45, 46]. Furthermore, MLL1 and SET7/9 could regulate a subset of TNFα-induced, NF-κB-dependent inflammatory genes in monocytes  and the high glucose-induced expression of NF-κB p65 and inflammatory genes in endothelial cells , indicating the diverse physiologic roles of MLL1 and SET7/9 in gene transactivation. Similarly, MLL1 and SET7/9 may also methylate other non-histone proteins and possibly even Smads in corneal fibroblasts. Further studies are needed to evaluate those possibilities. In the future, analogous approaches should be explored to examine epigenetic mechanisms of regulating the expression of other matrix genes in corneal epithelial cells exposed to TGFβ1. Epigenetic mechanisms may affect ECM expression by regulating the expression of metalloproteases and other proteases, because histone modification has been shown to regulate metalloproteases in some cells . Taken together, our results show that TGFβ1 can promote significant changes in H3K4 and H3K27 methylation on gene promoters in corneal fibroblasts that correlate with parallel increases in the expression of genes related to ECM accumulation and GCD2 pathogenesis.
In summary, our findings clearly show that epigenetic histone methylation modulates the expression of TGFBIp and ECM genes in corneal fibroblasts. In corneal fibroblasts reaching the quiescent state, the transcriptional repression of TGFBIp and ECM-associated genes occurs through heterochromatin formation with no external stimulation. H3K27 residues near SBEs within promoters are tri-methylated. During TGFβ1 stimulation, MLL1 and SET7/9 are activated, increasing their recruitment to SBEs. H3K4me1/3 becomes more methylated, and H3K27me3 becomes de-methylated on gene promoters, creating a favorable environment for Smad3 binding, resulting in the increased expression of TGFBIp and ECM-associated genes (Fig. 8c). The effective epigenetic regulation of histone H3K4me during the TGFβ1-mediated expression of TGFBIp and ECM genes in corneal fibroblasts could be used to create cornea-protective therapies for granular corneal dystrophy.
This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (No. 2011–0028699).
This research was supported by a Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF 2014R1A1A2057458)
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Munier FL, Korvatska E, Djemai A, Le Paslier D, Zografos L, Pescia G, et al. Kerato-epithelin mutations in four 5q31-linked corneal dystrophies. Nat Genet. 1997;15:247–51.View ArticlePubMedGoogle Scholar
- Korvatska E, Henry H, Mashima Y, Yamada M, Bachmann C, Munier FL, et al. Amyloid and non-amyloid forms of 5q31-linked corneal dystrophy resulting from kerato-epithelin mutations at Arg-124 are associated with abnormal turnover of the protein. J Biol Chem. 2000;275:11465–9.View ArticlePubMedGoogle Scholar
- Skonier J, Neubauer M, Madisen L, Bennett K, Plowman GD, Purchio AF. cDNA cloning and sequence analysis of beta ig-h3, a novel gene induced in a human adenocarcinoma cell line after treatment with transforming growth factor-beta. DNA Cell Biol. 1992;11:511–22.View ArticlePubMedGoogle Scholar
- Billings PC, Herrick DJ, Kucich U, Engelsberg BN, Abrams WR, Macarak EJ, et al. Extracellular matrix and nuclear localization of beta ig-h3 in human bladder smooth muscle and fibroblast cells. J Cell Biochem. 2000;79:261–73.View ArticlePubMedGoogle Scholar
- Andersen RB, Karring H, Moller-Pedersen T, Valnickova Z, Thogersen IB, Hedegaard CJ, et al. Purification and structural characterization of transforming growth factor beta induced protein (TGFBIp) from porcine and human corneas. Biochemistry. 2004;43:16374–84.View ArticlePubMedGoogle Scholar
- LeBaron RG, Bezverkov KI, Zimber MP, Pavelec R, Skonier J, Purchio AF. Beta IG-H3, a novel secretory protein inducible by transforming growth factor-beta, is present in normal skin and promotes the adhesion and spreading of dermal fibroblasts in vitro. J Invest Dermatol. 1995;104:844–9.View ArticlePubMedGoogle Scholar
- Kim JE, Jeong HW, Nam JO, Lee BH, Choi JY, Park RW, et al. Identification of motifs in the fasciclin domains of the transforming growth factor-beta-induced matrix protein betaig-h3 that interact with the alphavbeta5 integrin. J Biol Chem. 2002;277:46159–65.View ArticlePubMedGoogle Scholar
- Park SW, Bae JS, Kim KS, Park SH, Lee BH, Choi JY, et al. Beta ig-h3 promotes renal proximal tubular epithelial cell adhesion, migration and proliferation through the interaction with alpha3beta1 integrin. Exp Mol Med. 2004;36:211–9.View ArticlePubMedGoogle Scholar
- Klintworth GK. Advances in the molecular genetics of corneal dystrophies. Am J Ophthalmol. 1999;128:747–54.View ArticlePubMedGoogle Scholar
- Okada M, Yamamoto S, Inoue Y, Watanabe H, Maeda N, Shimomura Y, et al. Severe corneal dystrophy phenotype caused by homozygous R124H keratoepithelin mutations. Invest Ophthalmol Vis Sci. 1998;39:1947–53.PubMedGoogle Scholar
- Runager K, Basaiawmoit RV, Deva T, Andreasen M, Valnickova Z, Sorensen CS, et al. Human phenotypically distinct TGFBI corneal dystrophies are linked to the stability of the fourth FAS1 domain of TGFBIp. J Biol Chem. 2011;286:4951–8.View ArticlePubMedGoogle Scholar
- Yellore VS, Rayner SA, Aldave AJ. TGFB1-induced extracellular expression of TGFBIp and inhibition of TGFBIp expression by RNA interference in a human corneal epithelial cell line. Invest Ophthalmol Vis Sci. 2011;52:757–63.View ArticlePubMedPubMed CentralGoogle Scholar
- Jeon ES, Kim JH, Ryu H, Kim EK. Lysophosphatidic acid activates TGFBIp expression in human corneal fibroblasts through a TGF-beta1-dependent pathway. Cell Signal. 2012;24:1241–50.View ArticlePubMedGoogle Scholar
- Yam GH, Wang K, Jhanji V, Choy KW, Baum L, Pang CP. In vitro amyloid aggregate forming ability of TGFBI mutants that cause corneal dystrophies. Invest Ophthalmol Vis Sci. 2012;53:5890–8.View ArticlePubMedGoogle Scholar
- Sakharova OV, Taal MW, Brenner BM. Pathogenesis of diabetic nephropathy: focus on transforming growth factor-beta and connective tissue growth factor. Curr Opin Nephrol Hypertens. 2001;10:727–38.View ArticlePubMedGoogle Scholar
- Guha M, Xu ZG, Tung D, Lanting L, Natarajan R. Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes. FASEB J. 2007;21:3355–68.View ArticlePubMedGoogle Scholar
- Baricos WH, Reed JC, Cortez SL. Extracellular matrix degradation by cultured mesangial cells: mediators and modulators. Exp Biol Med (Maywood). 2003;228:1018–22.Google Scholar
- Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 2003;113:685–700.View ArticlePubMedGoogle Scholar
- Hua X, Liu X, Ansari DO, Lodish HF. Synergistic cooperation of TFE3 and smad proteins in TGF-beta-induced transcription of the plasminogen activator inhibitor-1 gene. Genes Dev. 1998;12:3084–95.View ArticlePubMedPubMed CentralGoogle Scholar
- Kato M, Zhang J, Wang M, Lanting L, Yuan H, Rossi JJ, et al. MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci U S A. 2007;104:3432–7.View ArticlePubMedPubMed CentralGoogle Scholar
- Kato M, Putta S, Wang M, Yuan H, Lanting L, Nair I, et al. TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol. 2009;11:881–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Schnaper HW, Hayashida T, Hubchak SC, Poncelet AC. TGF-beta signal transduction and mesangial cell fibrogenesis. Am J Physiol Renal Physiol. 2003;284:F243–52.View ArticlePubMedGoogle Scholar
- Berger SL. Histone modifications in transcriptional regulation. Curr Opin Genet Dev. 2002;12:142–8.View ArticlePubMedGoogle Scholar
- Shilatifard A. Chromatin modifications by methylation and ubiquitination: implications in the regulation of gene expression. Annu Rev Biochem. 2006;75:243–69.View ArticlePubMedGoogle Scholar
- Jenuwein T, Allis CD. Translating the histone code. Science. 2001;293:1074–80.View ArticlePubMedGoogle Scholar
- Martin C, Zhang Y. The diverse functions of histone lysine methylation. Nat Rev Mol Cell Biol. 2005;6:838–49.View ArticlePubMedGoogle Scholar
- Ruthenburg AJ, Allis CD, Wysocka J. Methylation of lysine 4 on histone H3: intricacy of writing and reading a single epigenetic mark. Mol Cell. 2007;25:15–30.View ArticlePubMedGoogle Scholar
- Hampsey M, Reinberg D. Tails of intrigue: phosphorylation of RNA polymerase II mediates histone methylation. Cell. 2003;113:429–32.View ArticlePubMedGoogle Scholar
- Shi Y, Whetstine JR. Dynamic regulation of histone lysine methylation by demethylases. Mol Cell. 2007;25:1–14.View ArticlePubMedGoogle Scholar
- Choi SI, Kim TI, Kim KS, Kim BY, Ahn SY, Cho HJ, et al. Decreased catalase expression and increased susceptibility to oxidative stress in primary cultured corneal fibroblasts from patients with granular corneal dystrophy type II. Am J Pathol. 2009;175:248–61.View ArticlePubMedPubMed CentralGoogle Scholar
- Pomraning KR, Smith KM, Freitag M. Genome-wide high throughput analysis of DNA methylation in eukaryotes. Methods. 2009;47:142–50.View ArticlePubMedGoogle Scholar
- Villeneuve LM, Reddy MA, Lanting LL, Wang M, Meng L, Natarajan R. Epigenetic histone H3 lysine 9 methylation in metabolic memory and inflammatory phenotype of vascular smooth muscle cells in diabetes. Proc Natl Acad Sci U S A. 2008;105:9047–52.View ArticlePubMedPubMed CentralGoogle Scholar
- Choi SI, Kim BY, Dadakhujaev S, Oh JY, Kim TI, Kim JY, et al. Impaired autophagy and delayed autophagic clearance of transforming growth factor beta-induced protein (TGFBI) in granular corneal dystrophy type 2. Autophagy. 2012;8:1782–97.View ArticlePubMedPubMed CentralGoogle Scholar
- Wang X, Zhu K, Li S, Liao Y, Du R, Zhang X, et al. MLL1, a H3K4 methyltransferase, regulates the TNFalpha-stimulated activation of genes downstream of NF-kappaB. J Cell Sci. 2012;125:4058–66.View ArticlePubMedGoogle Scholar
- Mishra BP, Ansari KI, Mandal SS. Dynamic association of MLL1, H3K4 trimethylation with chromatin and Hox gene expression during the cell cycle. FEBS J. 2009;276:1629–40.View ArticlePubMedGoogle Scholar
- Guenther MG, Jenner RG, Chevalier B, Nakamura T, Croce CM, Canaani E, et al. Global and Hox-specific roles for the MLL1 methyltransferase. Proc Natl Acad Sci U S A. 2005;102:8603–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Fischle W, Wang Y, Jacobs SA, Kim Y, Allis CD, Khorasanizadeh S. Molecular basis for the discrimination of repressive methyl-lysine marks in histone H3 by Polycomb and HP1 chromodomains. Genes Dev. 2003;17:1870–81.View ArticlePubMedPubMed CentralGoogle Scholar
- Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. Cell Res. 2011;21:381–95.View ArticlePubMedPubMed CentralGoogle Scholar
- Wang H, Cao R, Xia L, Erdjument-Bromage H, Borchers C, Tempst P, et al. Purification and functional characterization of a histone H3-lysine 4-specific methyltransferase. Mol Cell. 2001;8:1207–17.View ArticlePubMedGoogle Scholar
- Nishioka K, Chuikov S, Sarma K, Erdjument-Bromage H, Allis CD, Tempst P, et al. Set9, a novel histone H3 methyltransferase that facilitates transcription by precluding histone tail modifications required for heterochromatin formation. Genes Dev. 2002;16:479–89.View ArticlePubMedPubMed CentralGoogle Scholar
- Chuikov S, Kurash JK, Wilson JR, Xiao B, Justin N, Ivanov GS, et al. Regulation of p53 activity through lysine methylation. Nature. 2004;432:353–60.View ArticlePubMedGoogle Scholar
- Berger SL. The complex language of chromatin regulation during transcription. Nature. 2007;447:407–12.View ArticlePubMedGoogle Scholar
- Esteve PO, Chin HG, Benner J, Feehery GR, Samaranayake M, Horwitz GA, et al. Regulation of DNMT1 stability through SET7-mediated lysine methylation in mammalian cells. Proc Natl Acad Sci U S A. 2009;106:5076–81.View ArticlePubMedPubMed CentralGoogle Scholar
- Kouskouti A, Scheer E, Staub A, Tora L, Talianidis I. Gene-specific modulation of TAF10 function by SET9-mediated methylation. Mol Cell. 2004;14:175–82.View ArticlePubMedGoogle Scholar
- Ea CK, Baltimore D. Regulation of NF-kappaB activity through lysine monomethylation of p65. Proc Natl Acad Sci U S A. 2009;106:18972–7.View ArticlePubMedPubMed CentralGoogle Scholar
- Yang XD, Huang B, Li M, Lamb A, Kelleher NL, Chen LF. Negative regulation of NF-kappaB action by Set9-mediated lysine methylation of the RelA subunit. EMBO J. 2009;28:1055–66.View ArticlePubMedPubMed CentralGoogle Scholar
- Li Y, Reddy MA, Miao F, Shanmugam N, Yee JK, Hawkins D, et al. Role of the histone H3 lysine 4 methyltransferase, SET7/9, in the regulation of NF-kappaB-dependent inflammatory genes. Relevance to diabetes and inflammation. J Biol Chem. 2008;283:26771–81.View ArticlePubMedPubMed CentralGoogle Scholar
- El-Osta A, Brasacchio D, Yao D, Pocai A, Jones PL, Roeder RG, et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med. 2008;205:2409–17.View ArticlePubMedPubMed CentralGoogle Scholar
- Pons D, de Vries FR, van den Elsen PJ, Heijmans BT, Quax PH, Jukema JW. Epigenetic histone acetylation modifiers in vascular remodelling: new targets for therapy in cardiovascular disease. Eur Heart J. 2009;30:266–77.View ArticlePubMedGoogle Scholar